The Effects of a Cholinesterase Inhibitor Are Prominent in Patients With Fluctuating Cognition: A Part 3 Study of the Main Mechanism of Cholinesterase Inhibitors in Dementia
Authors:
- Marco OnofrjMOMarco Onofrj
- Astrid ThomasATAstrid Thomas
- Diego IaconoDiego Iacono
- Anna Lisa LucianoALAnna Lisa Luciano
- Angelo Di IorioAIAngelo Di Iorio
- 1 September 2003
- journal article
- clinical trial
- Published by Wolters Kluwer Health in Clinical Neuropharmacology
- Vol. 26 (5) , 239-251
Abstract
Fluctuating cognition is evidenced in different forms of dementia and is accompanied by electroencephalographic (EEG) abnormalities. The authors hypothesize that cholinesterase inhibitors are effective mostly in patients with fluctuating cognition. Twenty-three patients affected by mild dementia with similar scores on Mini-Mental State Examination (MMSE), Alzheimer Disease Assessment Scale-cognitive subscale (ADAS-cog), and Unified Parkinson's Disease Rating Scale evaluation were classified in a group with fluctuating cognition (n = 11) and a group of nonfluctuators (n = 12). All patients were assigned randomly to the branches of a double-blind crossover study of donepezil (DPZ), a 5 to 10-mg dose, versus vitamin E, a 2000 IU dose, for 30 days. MMSE, ADAS-cog, University of California at Los Angeles Neuropsychiatric Inventory (NPI), quantitative EEG, P3 event-related potentials, choice reaction time variability (CRTV) were assessed at baseline and at the end of treatments. At the end of the crossover study all patients received DPZ for 6 months. The dominant EEG frequency variability, low EEG frequencies amplitude, the P3 latency and jitter, CRTV, and NPI was significantly different in the fluctuating cognition group than the nonfluctuating group at baseline (P < 0.001). Short-term DPZ administration induced a significant increase in MMSE scores, reduction of ADAS-cog and of NPI scores (P < 0.003–0.001), increase of EEG α activity and reductions of P3 latency and jitter, dominant frequency variability and CRTV (P < 0.009-0.001) in the fluctuating cognition group, and significant increases of MMSE scores (P = 0.03) and a decrease of P3 jitter and dominant frequency variability (P < 0.034–0.041) in the nonfluctuating group. Short-term DPZ effects differed significantly between fluctuating cognition and nonfluctuating patients (0.001). Significant effects of the 6-month observation were observed only in fluctuating cognition patients. Logistic analysis showed that P3 latency predicts the effect of DPZ (P = 0.04, P < 0.01) in the crossover study, and CRTV predicts the effect at the 6-month follow-up.Keywords
This publication has 29 references indexed in Scilit:
- Donepezil Versus Vitamin E in Alzheimer's Disease Part 2: Mild Versus Moderate–Severe Alzheimer's DiseaseClinical Neuropharmacology, 2002
- Attention and Fluctuating Attention in Patients With Dementia With Lewy Bodies and Alzheimer DiseaseArchives of Neurology, 2001
- Donepezil, Rivastigmine, and Vitamin E in Alzheimer Disease: A Combined P300 Event-related Potentials/Neuropsychologic Evaluation over 6 MonthsClinical Neuropharmacology, 2001
- Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international studyThe Lancet, 2000
- Cholinergic deficits contribute to behavioral disturbance in patients with dementiaNeurology, 2000
- The Clinician Assessment of Fluctuation and the One Day Fluctuation Assessment ScaleThe British Journal of Psychiatry, 2000
- Quantifying fluctuation in dementia with Lewy bodies, Alzheimer’s disease, and vascular dementiaNeurology, 2000
- A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's diseaseNeurology, 1998
- Auditory long latency event-related potentials in Alzheimer's disease and multi-infarct dementia.Journal of Neurology, Neurosurgery & Psychiatry, 1988
- Brain electrical activity in patients with presenile and senile dementia of the Alzheimer typeAnnals of Neurology, 1984